01Adocia is specialized in Diabetes treatment, working with therapeutic proteins using a patented BioChaperone® technology to achieve personalized therapies
02Production in Lyon, France
03Market Research shows the need for better treatments in diabetic patients to reduce long-term consequences.
● The BioChaperone® technology is at the center of product strategy: 300 molecules are used to protect the drugs from degradation
● They also enhance the drug effect, are relatively inexpensive and tested in other treatments, improving the time and costs to market.
● Asia presence
A foot in China
● Tonghua Dongbao (THDB) is their partner in China, working to get their BioChaperone® Lispro ultra-fast insuline into the market.
● THDB also manufactures a Combo product of Glargine + Lispro using Adocia tech
● Dual Approach
Two hormones products
● The bi-hormonal M1Pram product, a mix of insulin and pramlintide improves blood sugar levels after eating, but also physiological functions during digestion, helping reduce symptons and weight gain for type 1 diabetes patients.
● M1Pram is in clinical trials and is seeing real interest from the scientific community and pharmaceutical companies, as can help with automatic artificial pancreas.
04A portfolio built on two axis: make known products better through chaperone proteins and innovate with two hormone combinations
Combo is premixed of a fast and slow insulin, reducing the daily injections to only two in more intense treatments — 65% of the chinese insulin market is this form of mixed products.
Biochaperone Lispro is a rapid insulin to use after eating
Their Glucagon product, a hormone that increases blood sugar, is the only one available for intramuscular injection, the quickest administration method in life-threatening conditions.
A mixed of insulin and a substance that activates the GLP1 receptor, it improves blood sugar ranges on patients needing more strength to control it.
The Glucagon GLP-1 mixes two hormones, glucagon and a substance called exenatide, that increase satiety, energy expenditure and slows down gastric emptying. Almost 13% of the world’s population is obese and more approaches to treat obesity are needed.
Is a multi-hormone treatment for type 1 diabetes,mixing insuline with Pramlintide that helps with weight loss and insuline levels controls. The mix make it easier for patients, reducing the number of daily injections, key to treatment effectiveness. The drug may also help diabetic patients with their cognitive decline.
B The Biz
05Adocia license their innovations to pharmaceutical companies which will finish development and commercialization. This approach focused on early development needs less capital and provides better ROI.
Adocia is open to partner with expertise in medical science, Late-stage clinical development, regulatory affairs and marketing
In 2018 Adocia and Chinese insulin leader Tonghua Dongbao Pharmaceuticals Co. Ltd entered into a strategic alliance to commercialize insulin products in mainland China.
Status: Series B
● CDC Enterprises
● Idinvest Partners
● Bioam Gestion
● ACG Management
● Societe Generale Asset Management
The company welcomes students and researchers each year and sponsors a class of the École Superieure de Physique et de Chimie Industrielles de la Ville de de Paris (ESPCI), supporting students professionalization.
06The number of diabetic patients is set to increase in the next decades around the world, specially in emerging countries
● The customers
Large pharmaceutical companies looking for innovation
Increased development of biosimilars and generics is obliging pharmaceutical companies to quickly replace their flagship products that have fallen into the public domain.
● Fully Engaged
Improved second generation
Adocia’s model fits with this approach, with the added advantage of improving existing products: it helps manage the medicinal product lifecycle by generating more efficient, patent-protected “second generation” agents for the companies that sell them
M The Market
07A global pandemic
Diabetes is a global pandemic, affecting more than 463 million people worldwide. Despite significant progress made in the treatment of diabetes over the last 30 years, there is still a significant medical need, with it estimated that nearly 79% of people with diabetes experience severe complications
● Emerging countries
More than 116 million of the 463 million people worldwide with diabetes live in China. Faced with this exponential growth, particularly in mass indications, these countries must rationalize healthcare costs.
+51% increase in the number of diabetic patients predicted in 2025
For all people with type 1 diabetes and around 25% of people with type 2 diabetes, insulin is a necessary treatment.
● Market data
In 2017, Novo Nordisk estimated that medicine and devices global costs for the treatment of diabetes were above $80 billion
P The People
08Adocia was founded in December 2005 by Gérard Soula and his two sons, Olivier and Rémi
37 Yrs old
Average employee age
80% on R&D
Employees working on
● Founder & CEO
Chairman of the Board of Directors and Chief Executive Officer of Adocia since 2005, PhD in organic chemistry, graduate of IAD in Aix-Marseille and then MBA of IAE in Marseille. Co-author of more than 120 patents.
Deputy CEO and R&D Director
holder of a PhD in polymer physico-chemistry, graduate of ENSIC Mulhouse and graduate of the MBA of IAE Lyon. Co-author of 40 patents.